Hemostasis Today

November, 2026
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Muhammet Özbilen: Rivaroxaban vs Apixaban – The Menstrual Bleeding Difference
Nov 20, 2026, 15:11

Muhammet Özbilen: Rivaroxaban vs Apixaban – The Menstrual Bleeding Difference

Muhammet Özbilen, Associate Professor Doctor at Ordu University, shared a post on LinkedIn about a recent article by Stephanie Quon et al., published in Blood Coagulation and Fibrinolysis, adding:

“Is Your Anticoagulant Draining Her Iron? Rivaroxaban vs Apixaban and HMB

A new meta-analysis by Quon, Ma and Tsang (UBC) in Blood Coagulation and Fibrinolysis, 2026, pooled 25 studies on menstrual bleeding with DOACs and VKAs.

Bottom line: for menstrual bleeding, apixaban looks clearly better than rivaroxaban.

  • HMB: about 3× higher odds with rivaroxaban (OR 2.83; 95% CI 2.11–3.81)
  • Anticoagulant changed or stopped because of menstrual bleeding: about 6× higher (OR 6.05; 1.91–19.19)
  • All four studies pointed the same way, as did the HEMBLED registry (HMB in 79% on rivaroxaban vs 53% on apixaban).

What it does not show

  • No difference in hospitalisation, transfusion or procedures (OR 1.04; 0.10–11.13), but events were rare, so this does not mean the drugs are equal.
  • It does not make apixaban ՛the best DOAC՛. Data on dabigatran and edoxaban are too limited.
  • DOACs vs VKA as a class: no clear answer. The risk depends on the drug, not the class.

Why this matters for iron deficiency

ISTH bleeding definitions miss most of this burden. Heavy periods that never reach a hospital still empty iron stores.

The result is fatigue, lower quality of life and quietly skipped doses, which raise VTE risk. Iron status was not measured in this meta-analysis. The authors flag it as a gap for future trials.

Practical takeaways

  • Take a menstrual history before starting anticoagulation (PBAC helps)․
  • Check CBC and ferritin at baseline and during follow-up․
  • Apixaban is a reasonable first choice for menstruating patients, especially with HMB, anaemia or iron deficiency․
  • If HMB develops on rivaroxaban, consider switching, plus iron replacement, hormonal therapy and a gynaecologic work-up․
  • Tell patients not to stop anticoagulation on their own․

Thrombotic risk, indication, organ function and drug interactions still come first.

Caveats

Mostly observational; 16 of 25 studies at serious risk of bias; no randomised head-to-head trials; each pooled estimate rests on only 2–4 small studies.”

Title: Heavy menstrual bleeding with direct oral anticoagulants and vitamin K antagonists: a systematic review and meta-analysis

Auhtors: Stephanie Quon, Lok In Josephine Ma, Peter Tsang

Muhammet Özbilen: Rivaroxaban vs Apixaban - The Menstrual Bleeding Difference

Stay updated with Hemostasis Today.